Major depressive disorder (MDD), is a prevalent mood disorder that associates with differential prefrontal brain expression patterns1. Treatment of MDD includes a variety of biopsychosocial approaches, but in medical practice, antidepressant drugs are the most common treatment for depressive episodes, and not surprisingly, they are among the most prescribed medications in North America2,3. While they are clearly effective, particularly for moderate to severe depressive episodes, there is important variability in how individuals respond to antidepressant treatment. Failure to respond has important individual, economic and social consequences for patients and their families4. Several lines of evidence demonstrate that genes are regulated through the activity of microRNAs (miRNAs), which act as fine–tuners and on–off switches in gene expression patterns5–7. Here we report on complementary studies using postmortem human brain samples, cellular assays and samples from clinical trials of depressed patients, and show that miR-1202, a miRNA specific to primates and enriched in the human brain, is differentially expressed in depressed individuals. Additionally, miR-1202 regulates the expression of the Metabotropic Glutamate Receptor 4 (GRM4) gene and predicts antidepressant response at baseline. These results suggest that miR-1202 is associated with the pathophysiology of depression and is a potential target for novel antidepressant treatments.

Somatodendritic (STD) dopamine (DA) release is a key mechanism for the autoregulatory control of DA release in the brain. However, its molecular mechanism remains undetermined. We tested the hypothesis that differential expression of synaptotagmin (Syt) isoforms explains some of the differential properties of terminal and STD DA release. Down-regulation of the dendritically expressed Syt4 and Syt7 severely reduced STD DA release, whereas terminal release required Syt1. Moreover, we found that although mobilization of intracellular Ca 2؉ stores is inefficient, Ca 2؉ influx through N-and P/Q-type voltage-gated channels is critical to trigger STD DA release. Our findings provide an explanation for the differential Ca 2؉ requirement of terminal and STD DA release. In addition, we propose that not all sources of intracellular Ca 2؉ are equally efficient to trigger this release mechanism. Our findings have implications for a better understanding of a fundamental cell biological process mediating transcellular signaling in a system critical for diseases such as Parkinson disease. Dopamine (DA),4 like other monoamine neurotransmitters, is released from the cell body and dendrites in addition to axon terminals (1). This process, called somatodendritic (STD) release, is important in the ventral tegmental area (VTA) for induction of behavioral sensitization to amphetamine through activation of local D1 receptors (2, 3) and in the substantia nigra (SN) for control of motor performance (4, 5). In addition, STD DA release modulates DA neuron firing activity through D2 autoreceptor activation (6, 7) and increases firing activity of SN pars reticulata ␥-aminobutyric acid-releasing neurons, a process that might activate feedback signals regulating DA neuron activity (8), thereby influencing axonal DA release.Two mechanisms have been proposed to mediate STD DA release: reversal of the DA transporter (9) and a vesicular exocytotic-like mechanism. In agreement with the second mechanism, STD DA release is activity-dependent (6, 10), sensitive to depletion of vesicular stores with reserpine (6, 11, 12), and Ca 2ϩ -dependent (6, 10, 12, 13). Moreover, disruption of SNARE proteins with botulinum toxins blocks STD DA release (10, 13). Vesicular exocytosis requires the concerted action of SNARE proteins and a synaptotagmin (Syt). During release, SNAREs have a direct role in vesicle-membrane fusion, and Syt acts as a Ca 2ϩ sensor. Of the 15 Syt isoforms identified so far, Syt1, 2, 3, 5, 6, 7, 9, and 10 have been reported to drive Ca 2ϩ -dependent vesicular fusion (14), and only Syt1, 2, and 9 are confirmed as Ca 2ϩ sensors for synaptic neurotransmitter release from axon terminals (15).One of the hallmarks of STD DA release is its relative persistence at reduced levels of extracellular Ca 2ϩ concentrations: although release from axon terminals is drastically reduced at extracellular Ca 2ϩ levels lower than 1 mM, STD DA release persists at Ca 2ϩ levels between 0.5 and 1 mM (Refs. 10, 12, and 13; but see also Ref. 16). This differential Ca 2...

Glutamate is the major excitatory transmitter in the brain. Vesicular glutamate transporters (VGLUT1-3) are responsible for uploading glutamate into synaptic vesicles. VGLUT1 and VGLUT2 are considered as specific markers of canonical glutamatergic neurons, while VGLUT3 is found in neurons previously shown to use other neurotransmitters than glutamate. Although there exists a rich literature on the localization of these glutamatergic markers in the rodent brain, little is currently known about the distribution of VGLUT1-3 in the human brain. In the present study, using subtype specific probes and antisera, we examined the localization of the three vesicular glutamate transporters in the human brain by in situ hybridization, immunoautoradiography and immunohistochemistry. We found that the VGLUT1 transcript was highly expressed in the cerebral cortex, hippocampus and cerebellum, whereas VGLUT2 mRNA was mainly found in the thalamus and brainstem. VGLUT3 mRNA was localized in scarce neurons within the cerebral cortex, hippocampus, striatum and raphe nuclei. Following immunoautoradiographic labeling, intense VGLUT1- and VGLUT2-immunoreactivities were observed in all regions investigated (cerebral cortex, hippocampus, caudate-putamen, cerebellum, thalamus, amygdala, substantia nigra, raphe) while VGLUT3 was absent from the thalamus and cerebellum. This extensive mapping of VGLUT1-3 in human brain reveals distributions that correspond for the most part to those previously described in rodent brains.